LeMaitre Vascular (NASDAQ:LMAT) Updates Q4 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its fourth quarter 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.750-0.81 for the period, compared to the consensus earnings per share estimate of 0.790. The company issued revenue guidance of $71.1 million-$73.1 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.

LeMaitre Vascular Price Performance

Shares of LMAT traded up $2.17 during mid-day trading on Tuesday, reaching $105.78. The company had a trading volume of 405,239 shares, compared to its average volume of 255,427. The company’s 50 day simple moving average is $97.27 and its 200 day simple moving average is $99.90. LeMaitre Vascular has a 1-year low of $79.39 and a 1-year high of $118.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of 39.03, a P/E/G ratio of 2.81 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The company had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%. Analysts expect that LeMaitre Vascular will post 3 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on LMAT shares. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Barrington Research restated an “outperform” rating and set a $120.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Citizens Jmp upped their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company increased their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $112.60.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at $155,428,765.11. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the transaction, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This represents a 56.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 54,453 shares of company stock worth $5,906,174. 7.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently made changes to their positions in the stock. Illinois Municipal Retirement Fund boosted its stake in LeMaitre Vascular by 1.1% during the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 123 shares in the last quarter. NewEdge Advisors LLC grew its holdings in LeMaitre Vascular by 4.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 139 shares during the period. Federated Hermes Inc. increased its stake in shares of LeMaitre Vascular by 0.4% during the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after purchasing an additional 155 shares in the last quarter. Equitable Holdings Inc. increased its stake in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier’s stock valued at $1,173,000 after purchasing an additional 205 shares in the last quarter. Finally, California State Teachers Retirement System lifted its holdings in shares of LeMaitre Vascular by 1.7% during the second quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier’s stock valued at $1,555,000 after purchasing an additional 316 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.